Regeneron Pharmaceuticals, Inc. is a biotechnology company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious diseases. The Company's commercialized medicines and product candidates in development are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, pain, infectious diseases, and rare diseases. It is also engaged in the research, development of monoclonal antibodies, which consists of Dupixent, Kevzara, and itepekimab. The Company's marketed products include EYLEA (aflibercept) Injection, Dupixent (dupilumab) Injection, Libtayo (cemiplimab) Injection, Praluent (alirocumab) Injection, Kevzara (sarilumab) Solution for Subcutaneous Injection, Inmazeb (atoltivimab, maftivimab, and odesivimab-ebgn) Injection, ARCALYST (rilonacept) Injection for Subcutaneous Use and ZALTRAP (ziv-aflibercept) Injection for Intravenous Infusion.
52 Week high
52 Week low
The Motley Fool • 3 days ago • REGNThis Recent FDA Approval Could Give Regeneron's Top Line a Big Boost
Seeking Alpha • 4 days ago • REGNRegeneron Pharmaceuticals: Game-Changing Discoveries In Healthcare
Market Watch • 8 days ago • REGNRegeneron's pricing deal with federal government may have ‘far-reaching consequences,' analysts say
Forbes • 12 days ago • REGNIs Regeneron Stock Fully Valued At $820?
Market Watch • 15 days ago • REGNRegeneron CFO Landry to retire, top accountant Fenimore to become CFO
Charts and pricing are provided for informational purposes only. The current market data is delayed up to 15 minutes. The accuracy of any market data displayed is not guaranteed.